OBJECTIVE To compare the efficacy of intravitreal bevacizumab and ranibizumab for the treatment of neovascular age-related macular degeneration using an as-needed treatment regimen. DESIGN Retrospective chart review. PARTICIPANTS One hundred and ninety two eyes of 184 patients. METHODS Patients received an initial treatment of 3 monthly intravitreal injections of ranibizumab or bevacizuma...

TO THE EDITOR: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF; Avastin, Genentech, South San Francisco, CA, and Roche, Basel, Switzerland), was approved in 2009 by the US Food and Drug Administration for the treatment of recurrent glioblastoma. The basis for this accelerated approval was uncontrolled phase II trials with a total of 215 patients; a single-arm...

BACKGROUND Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted. METHODS In a multicentre, randomised, double-blind, phase III trial, 649 patients with previously untreated metastatic ren...

Editor, A nti-VEGF agents, primarily bevacizumab, are emerging as a successful therapy for retinopathy of prematurity (ROP), particularly in aggressive posterior disease (Spandau et al. 2013). Concerns exist however regarding dosage, timing, duration of follow-up and long-term visual function. We conducted a prospective case– control study in 14 infants with symmetrical zone 1 or posterior zone...

Recognition of the role of vascular endothelial growth factor (VEGF) in developing the rich vascularity of glioblastomas, which contributes to their growth and resistance to radiation, surgery, and chemotherapy, has led to clinical trials of agents targeting VEGF or VEGF receptors 1 and 2. VEGF has been targeted with the mouse anti-human VEGF antibody avastin (bevacizumab), which has undergone ...

Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following bevacizumab ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration outpatient ROP screening examinations compared with infants, per current United States (US...

Bevacizumab-induced kidney side effects are common, mainly presented by blood hypertension (BH) and proteinuria (Pr), that generally resolve on drug withdrawal angiotensin-system blocker therapy. There is no standard threatment approach in cases of severe bevacizumab-induced injury associated with thrombotic microangiopathy (TMA). Eculizumab has been shown to be effective some these patients.

We hereby report a case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy (CSC). Issues regarding safety and adverse effects of bevacizumab are discussed. To the best of our knowledge, this is the first reported case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal CSC.

I nterest in and controversy over the use of bevacizumab (Avastin; Genentech/Roche, South San Francisco, CA) for the treatment of retinopathy of prematurity (ROP) have increased dramatically after the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study. Off-label bevacizumab has been used extensively for age-related macular degeneration (AMD) for more tha...

PURPOSE To identify mediators of glioblastoma antiangiogenic therapy resistance and target these mediators in xenografts. EXPERIMENTAL DESIGN We conducted microarray analysis comparing bevacizumab-resistant glioblastomas (BRG) with pretreatment tumors from the same patients. We established novel xenograft models of antiangiogenic therapy resistance to target candidate resistance mediator(s). ...